KPTI Karyopharm Therapeutics Inc.: institutional ownership and insider trading
104 funds reported holding $227M of Karyopharm Therapeutics Inc. in their latest 13F filings; in Q2 2026 funds net sold $24.2M, with 33 new positions and 17 funds selling out; over the last 12 months insiders bought $0 and sold $351K on the open market.
Famous investors holding KPTI
- Two Sigma (Two Sigma Investments): $6.79M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $3.34M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $1.15M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $1.06M, 0.0% of the portfolio
Largest institutional holders of KPTI
- RA CAPITAL MANAGEMENT, L.P. — $18.7M
- ADAGE CAPITAL PARTNERS GP, L.L.C. — $14.9M
- ACORN CAPITAL ADVISORS, LLC — $14.8M
- GOLDMAN SACHS GROUP INC (GS, GSCE, GS-PA, GS-PC, GS-PD) — $13.9M
- BlackRock, Inc. (BLK) — $13.9M
- VANGUARD CAPITAL MANAGEMENT LLC — $9.37M
- Catalio Capital Management, LP — $9.19M
- Avidity Partners Management LP — $9.03M
- T. Rowe Price Investment Management, Inc. — $7.68M
- TWO SIGMA INVESTMENTS, LP — $6.79M
Recent KPTI insider trades
- Oct 16, 2026: Abate Kristin sold 4,788 shares ($1.65K)
- Oct 1, 2026: Abate Kristin sold 378 shares ($450)
- Sep 1, 2026: Abate Kristin sold 19 shares ($38)
- Jul 28, 2026: Poulton Stuart sold 189 shares ($1.34K)
5%+ owners
- RA Capital Management, L.P.: 9.9% (Schedule 13G/A, filed Aug 14, 2026)
- Affinity Asset Advisors, LLC: 8.6% (Schedule 13G/A, filed May 14, 2026)
- Adage Capital Management, L.P.: 6.8% (Schedule 13G/A, filed Aug 12, 2026)
- T. Rowe Price Investment Management, Inc.: 6.6% (Schedule 13G/A, filed Jun 5, 2026)
- THE GOLDMAN SACHS GROUP, INC.: 6.3% (Schedule 13G/A, filed Aug 11, 2026)
- Integrated Core Strategies (US) LLC: 5.7% (Schedule 13G, filed Sep 4, 2026)